These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15804353)

  • 41. Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis.
    Sirgel FA; Tait M; Warren RM; Streicher EM; Böttger EC; van Helden PD; Gey van Pittius NC; Coetzee G; Hoosain EY; Chabula-Nxiweni M; Hayes C; Victor TC; Trollip A
    Microb Drug Resist; 2012 Apr; 18(2):193-7. PubMed ID: 21732736
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Primary drug resistance pattern of mycobacterium tuberculosis in Dhaka, Bangladesh.
    Miah MR; Ali MS; Saleh AA; Sattar H
    Bangladesh Med Res Counc Bull; 2000 Aug; 26(2):33-40. PubMed ID: 11508069
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mycobacterium tuberculosis rrs A1401G mutation correlates with high-level resistance to kanamycin, amikacin, and capreomycin in clinical isolates from mainland China.
    Du Q; Dai G; Long Q; Yu X; Dong L; Huang H; Xie J
    Diagn Microbiol Infect Dis; 2013 Oct; 77(2):138-42. PubMed ID: 23948547
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The action of new antituberculous drugs on intracellular tubercle bacilli.
    Clini V; Grassi C
    Antibiot Chemother; 1970; 16():20-6. PubMed ID: 4108888
    [No Abstract]   [Full Text] [Related]  

  • 45. Pyranocoumarin, a novel anti-TB pharmacophore: synthesis and biological evaluation against Mycobacterium tuberculosis.
    Xu ZQ; Pupek K; Suling WJ; Enache L; Flavin MT
    Bioorg Med Chem; 2006 Jul; 14(13):4610-26. PubMed ID: 16513358
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Activity of rifampin against Mycobacterium tuberculosis in a reference center.
    Ruiz P; Gutierrez J; Rodríguez-Cano F; Zerolo FJ; Casal M
    Microb Drug Resist; 2004; 10(3):239-42. PubMed ID: 15383168
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis.
    Singh S; Roy KK; Khan SR; Kashyap VK; Sharma A; Jaiswal S; Sharma SK; Krishnan MY; Chaturvedi V; Lal J; Sinha S; Dasgupta A; Srivastava R; Saxena AK
    Bioorg Med Chem; 2015 Feb; 23(4):742-52. PubMed ID: 25614114
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of detection and drug resistance of Mycobacterium tuberculosis in patients in the Łódzkie voivodship in 2009-2013.
    Majewski K; Rybczyńska M; Wódz K
    Przegl Epidemiol; 2015; 69(3):453-8, 575-80. PubMed ID: 26519839
    [TBL] [Abstract][Full Text] [Related]  

  • 49. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
    Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
    Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence.
    Wayne LG; Hayes LG
    Infect Immun; 1996 Jun; 64(6):2062-9. PubMed ID: 8675308
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [STUDY OF THE IN VITRO ANTIBACILLARY ACTION OF CAPREOMYCIN].
    COLETSOS PJ; ORIOT E
    Rev Tuberc Pneumol (Paris); 1964 Apr; 28():413-32. PubMed ID: 14194722
    [No Abstract]   [Full Text] [Related]  

  • 53. Bactericidal activity of nitrofurans against growing and dormant Mycobacterium bovis BCG.
    Murugasu-Oei B; Dick T
    J Antimicrob Chemother; 2000 Dec; 46(6):917-9. PubMed ID: 11102410
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cholesterol-dependent activity of dapsone against non-replicating persistent mycobacteria.
    Gibson SER; Harrison J; Molloy A; Cox JAG
    Microbiology (Reading); 2022 Dec; 168(12):. PubMed ID: 36748615
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [ON THE PROBLEM OF ANTIMYCOBACTERIAL EFFECT AND CROSS RESISTANCE OF CAPREOMYCIN].
    TRNKA L; KUSKA J; HAVEL A
    Prax Pneumol; 1964 Dec; 18():798-802. PubMed ID: 14335595
    [No Abstract]   [Full Text] [Related]  

  • 56. Capreomycin laboratory studies.
    Bloom C
    Antibiot Chemother; 1970; 16():1-9. PubMed ID: 4108887
    [No Abstract]   [Full Text] [Related]  

  • 57. Benzene Amide Ether Scaffold is Active against Non-replicating and Intracellular
    Ahmed S; Chowdhury S; Gomez J; Hung DT; Parish T
    ACS Infect Dis; 2023 Oct; 9(10):1981-1992. PubMed ID: 37708378
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Differential Gene Expression Pattern of Mycobacterium tuberculosis in Response to Capreomycin and PA-824 versus First-Line TB Drugs Reveals Stress- and PE/PPE-Related Drug Targets.
    Fu LM; Tai SC
    Int J Microbiol; 2009; 2009():879621. PubMed ID: 20016672
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria.
    Campos DL; Demarqui FM; Solcia MC; de Souza PC; da Silva Maia PI; Deflon VM; Pavan FR
    Biomedicines; 2022 Sep; 10(10):. PubMed ID: 36289661
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro microbiological characterization of novel cyclic homopentapeptides, CP-101,680 and CP-163,234, for animal health use.
    Norcia LJ; Silvia AM; Dirlam JP; Schnur RC; Bergeron JM; Retsema JA; Hayashi SF
    J Antibiot (Tokyo); 1999 Nov; 52(11):1007-16. PubMed ID: 10656573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.